Shionogi Highlights Japan’s Role in Advancing Global Health in Dialogue with Bill Gates - Discuss...

Shionogi Highlights Japan’s Role in Advancing Global Health in Dialogue with Bill Gates - Discussing the Fight Against Infectious Diseases and the Future of Sustainable Healthcare Models under the Theme “Japan’s Role in Advancing Global Health Progres  Shionogi Inc.

Shionogi to Acquire Japan Tobacco’s Pharmaceutical Business - TipRanks

Shionogi to Acquire Japan Tobacco’s Pharmaceutical Business  TipRanks

Is It Smart To Buy Shionogi & Co., Ltd. (TSE:4507) Before It Goes Ex-Dividend? - simplywall.st

Is It Smart To Buy Shionogi & Co., Ltd. (TSE:4507) Before It Goes Ex-Dividend?  simplywall.st

BioVersys and Shionogi agree to develop ansamycin leads - Pharmaceutical Technology

BioVersys and Shionogi agree to develop ansamycin leads  Pharmaceutical Technology

Can Shionogi’s Rally Continue After Key Drug Approval in 2025? - Yahoo Finance

Can Shionogi’s Rally Continue After Key Drug Approval in 2025?  Yahoo Finance

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - C...

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention  Contagion Live

Shionogi to buy Japan Tobacco's pharma units for over $1B - FirstWord Pharma

Shionogi to buy Japan Tobacco's pharma units for over $1B  FirstWord Pharma

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - Fierce Biotech

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program  Fierce Biotech

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 F...

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure  Business Wire

Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge - JAPAN Forward

Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge  JAPAN Forward

FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP - Infectious Disease Special Edition

FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP  Infectious Disease Special Edition

Shionogi Implements Stibo Systems MDM Solution - PR Newswire

Shionogi Implements Stibo Systems MDM Solution  PR Newswire

Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion - Reuters

Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion  Reuters

Accelerating drug discovery with AI innovation - SAS: Data and AI Solutions

Accelerating drug discovery with AI innovation  SAS: Data and AI Solutions

Shionogi to acquire Japan Tobacco pharma companies for $1.1B - BioWorld MedTech

Shionogi to acquire Japan Tobacco pharma companies for $1.1B  BioWorld MedTech

Enrollment Update - Shionogi Inc.

Enrollment Update  Shionogi Inc.

Shionogi awarded $375m from HHS for preventative Covid-19 injectable - Pharmaceutical Technology

Shionogi awarded $375m from HHS for preventative Covid-19 injectable  Pharmaceutical Technology

Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma

Shionogi strikes research and option deal with BioVersys for antibacterial assets  FirstWord Pharma

Sponsorship of the 25th Summer Deaflympics Tokyo 2025｜ 塩野義製薬 - Shionogi Inc.

Sponsorship of the 25th Summer Deaflympics Tokyo 2025｜ 塩野義製薬  Shionogi Inc.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Reaches New 12-Month High - What's Next? - M...

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Reaches New 12-Month High - What's Next?  MarketBeat

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs - Bloomberg.com

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs  Bloomberg.com

Shionogi pushes 2030 vision forward with $1 billion acquisition - The Pharma Letter

Shionogi pushes 2030 vision forward with $1 billion acquisition  The Pharma Letter

Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults - Fierce Biotech

Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults  Fierce Biotech

BioVersys joins forces with Shionogi on ansamycin development - The Pharma Letter

BioVersys joins forces with Shionogi on ansamycin development  The Pharma Letter

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek - Business Wire

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek  Business Wire

Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial - Clinical Trials A...

Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial  Clinical Trials Arena

Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients - 2 Minute Medicine

Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients  2 Minute Medicine

Shionogi puts up to $600m behind BioVersys antibiotics - pharmaphorum

Shionogi puts up to $600m behind BioVersys antibiotics  pharmaphorum

Clinigen and Shionogi CEOs meet for signing ceremony - European Pharmaceutical Manufacturer

Clinigen and Shionogi CEOs meet for signing ceremony  European Pharmaceutical Manufacturer

Shionogi inks new hearing loss research deal with Cilcare - The Pharma Letter

Shionogi inks new hearing loss research deal with Cilcare  The Pharma Letter

Shionogi strengthens position by acquiring Torii - MarketScreener

Shionogi strengthens position by acquiring Torii  MarketScreener

Clinigen and Shionogi formalize licensing pact for cefiderocol - The Pharma Letter

Clinigen and Shionogi formalize licensing pact for cefiderocol  The Pharma Letter

Shionogi & Co., Ltd. Just Recorded A 8.7% EPS Beat: Here's What Analysts Are Forecasting Next - s...

Shionogi & Co., Ltd. Just Recorded A 8.7% EPS Beat: Here's What Analysts Are Forecasting Next  simplywall.st

Bioversys, Shionogi in CHF529M lung infection collaboration - BioWorld MedTech

Bioversys, Shionogi in CHF529M lung infection collaboration  BioWorld MedTech

Shionogi aims to buy tobacco giant's pharma unit for $1bn - pharmaphorum

Shionogi aims to buy tobacco giant's pharma unit for $1bn  pharmaphorum

Development of a Manufacturing Process for S-892216 Part I: A Novel Method for Constructing a Mul...

Development of a Manufacturing Process for S-892216 Part I: A Novel Method for Constructing a Multi-Substituted Barbiturate Skeleton for Scalable Synthesis  ACS Publications

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan - Business ...

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan  Business Wire

BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants - BioWorld MedTech

BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants  BioWorld MedTech

Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug - Bloomberg Law News

Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug  Bloomberg Law News

Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary - TipRanks

Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary  TipRanks

The Leadership Connection - thebossmagazine.com

The Leadership Connection  thebossmagazine.com

Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants - BioWorld MedTech

Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants  BioWorld MedTech

Ceolia takes over from Shionogi in marketing of Actair in Japan - The Pharma Letter

Ceolia takes over from Shionogi in marketing of Actair in Japan  The Pharma Letter

Eyes on Asia: Chugai, Mabwell, Shionogi - BioXconomy

Eyes on Asia: Chugai, Mabwell, Shionogi  BioXconomy

Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs - Nikkei Asia

Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs  Nikkei Asia

Bristol Myers’ $40B US investment; Shionogi to buy Japanese drugmaker - Endpoints News

Bristol Myers’ $40B US investment; Shionogi to buy Japanese drugmaker  Endpoints News

Action to Implement Management that is Conscious of Cost of Capital and Stock Price | IR Library ...

Action to Implement Management that is Conscious of Cost of Capital and Stock Price | IR Library | Shionogi & Co., Ltd.  Shionogi Inc.

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting...

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations  Business Wire

Swiss firm BioVersys signs deal with Shionogi for antibiotics research - SWI swissinfo.ch

Swiss firm BioVersys signs deal with Shionogi for antibiotics research  SWI swissinfo.ch

Shionogi & Co. Reports Strong Q1 2025 Earnings Growth - The Globe and Mail

Shionogi & Co. Reports Strong Q1 2025 Earnings Growth  The Globe and Mail

BioVersys inks deal worth CHF 479 M with Japan's Shionogi to treat infectious diseases - BioSpect...

BioVersys inks deal worth CHF 479 M with Japan's Shionogi to treat infectious diseases  BioSpectrum Asia

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral - The Pharma Letter

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral  The Pharma Letter

Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma - Bloomberg.com

Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma  Bloomberg.com

Shionogi gets approval in Japan for ADHD digital therapeutic - pharmaphorum

Shionogi gets approval in Japan for ADHD digital therapeutic  pharmaphorum

What drives Shionogi Co Ltd SH0 stock price - Risk-Reward Ratio Analysis & Free High Frequency Tr...

What drives Shionogi Co Ltd SH0 stock price - Risk-Reward Ratio Analysis & Free High Frequency Trading Ideas  earlytimes.in

Pharmalittle: We're reading about conflicts on U.S. vaccine panels, pharma DTC sales, and much mo...

Pharmalittle: We're reading about conflicts on U.S. vaccine panels, pharma DTC sales, and much more  statnews.com

Japan's Shionogi announces further agreement with Apnimed for sleep disorder treatments - BioSpec...

Japan's Shionogi announces further agreement with Apnimed for sleep disorder treatments  BioSpectrum Asia

Apnimed Provides Clinical Updates for Multiple Product Candidates - PR Newswire

Apnimed Provides Clinical Updates for Multiple Product Candidates  PR Newswire

Apnimed Acquires Global Rights to Additional Sleep Apnea Drug Candidate - Sleep Review

Apnimed Acquires Global Rights to Additional Sleep Apnea Drug Candidate  Sleep Review

Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia - GlobeNewswire

Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia  GlobeNewswire

Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal - Nikkei Asia

Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal  Nikkei Asia

His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone ...

His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone  CalMatters

Development of a Manufacturing Process for S-892216 Part II: Improvements Toward Commercially Fea...

Development of a Manufacturing Process for S-892216 Part II: Improvements Toward Commercially Feasible Process  ACS Publications

Nxera and Shionogi launch Quviviq in Japan - The Pharma Letter

Nxera and Shionogi launch Quviviq in Japan  The Pharma Letter

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops - insights.citeline.com

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops  insights.citeline.com

Japan's Shionogi to acquire Torii Pharmaceutical from Japan Tobacco for $1 billion - MLex

Japan's Shionogi to acquire Torii Pharmaceutical from Japan Tobacco for $1 billion  MLex

Japan's Shionogi inks new partnership agreement to support antimicrobial stewardship in Kenya - B...

Japan's Shionogi inks new partnership agreement to support antimicrobial stewardship in Kenya  BioSpectrum Asia

Ironwood’s layoffs; Shionogi’s RSV pill succeeds in Phase 2 - Endpoints News

Ironwood’s layoffs; Shionogi’s RSV pill succeeds in Phase 2  Endpoints News

Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission - Reuters

Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission  Reuters

Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout - Fierce P...

Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout  Fierce Pharma

A Pill to Prevent COVID-19 Shows Promise - Time Magazine

A Pill to Prevent COVID-19 Shows Promise  Time Magazine

Ensitrelvir Effective as Oral Antiviral for Postexposure Prophylaxis Against COVID-19 - Pharmacy ...

Ensitrelvir Effective as Oral Antiviral for Postexposure Prophylaxis Against COVID-19  Pharmacy Times

Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand - BioSpectrum Asia

Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand  BioSpectrum Asia

Positive Phase III trial results for ensitrelvir - The Pharma Letter

Positive Phase III trial results for ensitrelvir  The Pharma Letter

China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi - Yi...

China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi  Yicai Global

Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO - Eura...

Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO  Euractiv

Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study - FirstWord Pharma

Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study  FirstWord Pharma

Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome,...

Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder  BioSpace

Recon: Novo Nordisk to sell discounted GLP-1s at the pharmacies; FDA’s absence from international...

Recon: Novo Nordisk to sell discounted GLP-1s at the pharmacies; FDA’s absence from international standards meetings imperils U.S. leadership  Regulatory Affairs Professionals Society | RAPS

First-Generation Process Development for the Synthesis of Baloxavir Marboxil: Early-Stage Develop...

First-Generation Process Development for the Synthesis of Baloxavir Marboxil: Early-Stage Development of Synthetic Methods to Prepare Baloxavir Marboxil Intermediates  ACS Publications

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment - Precedence Research

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment  Precedence Research

Apnimed doses first subject in trial for sleep apnoea with central component - Clinical Trials Arena

Apnimed doses first subject in trial for sleep apnoea with central component  Clinical Trials Arena

Shionogi’s ensitrelvir prevents symptomatic COVID-19 - The Pharma Letter

Shionogi’s ensitrelvir prevents symptomatic COVID-19  The Pharma Letter

Fierce Pharma Asia—Takeda's next CEO; Enhertu's novel FDA nod; East Asian American C-suite execs ...

Fierce Pharma Asia—Takeda's next CEO; Enhertu's novel FDA nod; East Asian American C-suite execs  Fierce Pharma

Even More Studies From IDWeek 2024 to Improve Lives: CSL Seqirus and Shionogi - Infection Control...

Even More Studies From IDWeek 2024 to Improve Lives: CSL Seqirus and Shionogi  Infection Control Today

Preparing Europe for the next cross-border health threats, COVID lessons unpacked - Euractiv

Preparing Europe for the next cross-border health threats, COVID lessons unpacked  Euractiv

Masahiro Fujita - Shionogi Inc.

Masahiro Fujita  Shionogi Inc.

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19  National Institutes of Health (NIH) | (.gov)

Japan's Shionogi inks agreement with Osaka Metropolitan University to establish model for city re...

Japan's Shionogi inks agreement with Osaka Metropolitan University to establish model for city resilient to infectious diseases  BioSpectrum Asia

Chronic Refractory Cough Market Size to Reach USD 14.9 Billion by 2035, Impelled by Increasing Re...

Chronic Refractory Cough Market Size to Reach USD 14.9 Billion by 2035, Impelled by Increasing Research & Development Activities  BioSpace

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Government, and Academia to Tackle Infectious Diseases  Shionogi Inc.

Shionogi to acquire Qpex Biopharma for $140m - Pharmaceutical Technology

Shionogi to acquire Qpex Biopharma for $140m  Pharmaceutical Technology

Notice of Head Office Relocation｜ 塩野義製薬 - Shionogi Inc.

Notice of Head Office Relocation｜ 塩野義製薬  Shionogi Inc.

Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Mat...

Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Maternal and Child Health in Kenya and Ghana  Shionogi Inc.

History - Shionogi Inc.

History  Shionogi Inc.

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aimed at maximizing value  Shionogi Inc.

Tadashi Hara - Shionogi Inc.

Tadashi Hara  Shionogi Inc.

Nathan McCutcheon - Shionogi Inc.

Nathan McCutcheon  Shionogi Inc.

Pharma sector sees $6.96 billion in global deal activity in May 2025, led by GSK, Shionogi, and E...

Pharma sector sees $6.96 billion in global deal activity in May 2025, led by GSK, Shionogi, and Eli Lilly: GlobalData  Express Pharma

Japanese drug shows promise in preventing COVID-19 infection - R&D World

Japanese drug shows promise in preventing COVID-19 infection  R&D World